Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. [electronic resource]
Producer: 20130306Description: e45492 p. digitalISSN:- 1932-6203
- Animals
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- administration & dosage
- Apoptosis -- drug effects
- Caspases -- metabolism
- Cell Death -- drug effects
- Cell Line, Tumor
- Cell Survival -- drug effects
- Dacarbazine -- administration & dosage
- Drug Synergism
- Female
- Humans
- Inhibitor of Apoptosis Proteins -- metabolism
- Melanoma -- metabolism
- Mice
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Receptors, TNF-Related Apoptosis-Inducing Ligand -- agonists
- Tumor Stem Cell Assay
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.